How Enabling Drug Delivery Innovation Gets Better Medicines to Patients
Last year Moderna’s former head of infectious disease described vaccine lipid nanoparticle (LNP) delivery technology “unsung hero of the whole thing.” The whole thing being the mRNA COVID-19 vaccine administered to hundreds of millions around the globe, through both Pfizer and Moderna. Proper delivery that protected the fragile messenger RNA molecular was critical in making […]
How Alloy is Democratizing T Cell Receptor (TCR) Therapy Discovery
At Alloy Therapeutics our goal is to empower drug discovery teams with technologies and services enabling them to make the best medicines for patients. Our company started this work in antibodies with a long-term plan to expand innovation to “adjacent modalities” that require similar expertise and could leverage much of our core antibody discovery, protein […]
How Alloy Will Help the Drug Discovery Community Unlock the Therapeutic Potential of ASOs
Our mission has always been to democratize biologics discovery technology and capabilities so that the widest possible audience of scientists can access them to develop promising therapeutics for patients. We both create platforms and build discovery services groups that are expert in using and improving these platforms for the benefit of all. We are excited […]
How Our Mytide Investment Supports the Peptides Ecosystem
Peptides are a promising therapeutic modality in that they are small and specific in their targeting, while being relatively inexpensive to manufacture. Insulin is perhaps the best-known therapeutic peptide, but since 2000 33 non-insulin peptide therapeutics have been approved, spanning treatments for HIV, chronic pain, metabolic disease, cancer, cardiovascular disease, and more. Improvements in production, […]
Partnering with Target-Rich Biotech Companies
Running a successful early-stage biotech company requires a careful balance of enterprise and discipline. Companies must develop disruptive new discovery technologies or insights into disease biology that can have broad applications, but they must choose their first disease application(s) carefully. This tension is in large part driven by the demands around financing a startup biotech […]
Democratizing Access for Academic Entrepreneurs
We are advancing Alloy as a biotechnology ecosystem company, because we believe strongly that the innovation and breakthroughs that result from a network of relationships are far more powerful than those that can advance from silos. We collaborate with everyone to compete against disease. An exciting element of this dynamic is how under-resourced, smaller teams […]